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Abstract
Background: Platelets are associated with HIV in the blood of infected individuals and might modulate viral 
dissemination, particularly if the virus is directly transmitted into the bloodstream. The C-type lectin DC-SIGN and the 
novel HIV attachment factor CLEC-2 are expressed by platelets and facilitate HIV transmission from platelets to T-cells. 
Here, we studied the molecular mechanisms behind CLEC-2-mediated HIV-1 transmission.
Results: Binding studies with soluble proteins indicated that CLEC-2, in contrast to DC-SIGN, does not recognize the 
viral envelope protein, but a cellular factor expressed on kidney-derived 293T cells. Subsequent analyses revealed that 
the cellular mucin-like membranous glycoprotein podoplanin, a CLEC-2 ligand, was expressed on 293T cells and 
incorporated into virions released from these cells. Knock-down of podoplanin in 293T cells by shRNA showed that 
virion incorporation of podoplanin was required for efficient CLEC-2-dependent HIV-1 interactions with cell lines and 
platelets. Flow cytometry revealed no evidence for podoplanin expression on viable T-cells and peripheral blood 
mononuclear cells (PBMC). Podoplanin was also not detected on HIV-1 infected T-cells. However, apoptotic bystander 
cells in HIV-1 infected cultures reacted with anti-podoplanin antibodies, and similar results were obtained upon 
induction of apoptosis in a cell line and in PBMCs suggesting an unexpected link between apoptosis and podoplanin 
expression. Despite the absence of detectable podoplanin expression, HIV-1 produced in PBMC was transmitted to T-
cells in a CLEC-2-dependent manner, indicating that T-cells might express an as yet unidentified CLEC-2 ligand.
Conclusions: Virion incorporation of podoplanin mediates CLEC-2 interactions of HIV-1 derived from 293T cells, while 
incorporation of a different cellular factor seems to be responsible for CLEC-2-dependent capture of PBMC-derived 
viruses. Furthermore, evidence was obtained that podoplanin expression is connected to apoptosis, a finding that 
deserves further investigation.
Background
The envelope protein (Env) of the human immunodefi-
ciency virus (HIV), a heavily glycosylated type I trans-
membrane protein, mediates infectious viral entry into
target cells [1]. This process depends on the interactions
of Env with proteins displayed at the surface of host cells.
All primary HIV-1 isolates characterized to date engage
the CD4 protein as receptor for infectious entry [2,3].
Upon binding to CD4, a coreceptor binding site is gener-
ated or exposed in Env, which allows engagement of the
chemokine coreceptors CCR5 and CXCR4. The interac-
tions of Env with CD4 and coreceptor are essential for
infectious entry, and the interacting surfaces are key tar-
gets for preventive and therapeutic approaches [2,3]. For
instance, a small molecule inhibitor of Env binding to
CCR5, maraviroc, blocks spread of CCR5-tropic HIV and
is used as salvage therapy for patients who do not
respond to conventional HIV therapy [4,5].
Receptor expression levels can limit HIV entry into
host cells [6,7], and this limitation can be overcome by
concentrating virions onto target cells by, for example,
centrifugation or polybrene treatment [8]. A constantly
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accumulating body of evidence suggests that certain host
cell factors can also promote viral attachment to cells and
can thereby increase infection efficiency [9,10]. A striking
example is the interaction of HIV with a semen-derived
fragment of prostatic acidic phosphatase, termed SEVI
(for Semen Enhancer of Virus Infection) [11]. SEVI, an
amyloidogenic peptide, forms fibrils in human semen
which capture HIV and concentrate virions onto target
cells [11]. As a consequence, SEVI boosts viral infectivity
and might increase the risk of acquiring HIV infection
upon sexual intercourse. Incorporation of host cell fac-
tors into the HIV envelope can also increase viral infec-
tivity. The augmentation of infectivity is due to the
interaction of the virion-incorporated factors with their
cognate receptors on HIV target cells, as exemplified by
the up to 100-fold increased infectivity of ICAM-1-bear-
ing viruses for LFA-1 positive target cells [12,13]. Finally,
attachment of HIV to dendritic cells can also promote
HIV infection of adjacent T-cells [14,15], and this prop-
erty has been associated with the expression of DC-SIGN
[16], a calcium-dependent (C-type) lectin which recog-
nizes mannose-rich carbohydrates on the HIV Env pro-
tein [17-19]. Engineered expression of DC-SIGN on
certain cell lines promotes receptor-dependent infection
of these cells (termed infection in cis) [20] or of adjacent
target cells (termed infection in trans, or transmission)
[16], and it has been suggested that DC-SIGN might pro-
mote HIV spread in and between individuals [16]. How-
ever, this hypothesis is intensely debated [21-25]. In fact,
several lines of evidence suggest that DC-SIGN might
mainly function as a pathogen recognition receptor,
which promotes HIV uptake for MHC presentation and
thereby exerts a protective function against HIV infection
[23-27].
We and others have previously shown that apart from
dendritic cells, platelets also express DC-SIGN and that
these cell fragments bind to HIV in a mainly DC-SIGN-
dependent manner [28,29]. However, the HIV binding
activity of platelets could be partially inhibited by antisera
specific for the newly identified HIV attachment factor
CLEC-2 [29], indicating that CLEC-2 contributes to HIV
capture by platelets. CLEC-2 is a lectin-like protein, and
its putative carbohydrate recognition sequence contains
17 amino acid residues highly conserved between C-type
lectins [30]. Binding of the snake venom toxin rhodocytin
to CLEC-2 triggers Syk-dependent signalling in platelets
which causes platelet degranulation [31,32]. Residues in
CLEC-2 which are required for binding to rhodocytin
have been defined [33,34]. However, it is at present
unclear how CLEC-2 interacts with HIV.
Here, we report that CLEC-2, unlike DC-SIGN, does
not bind to the viral Env protein, but to a cellular factor
incorporated into the viral envelope. For viruses pro-
duced in the kidney-derived cell line 293T, this factor was
found to be podoplanin (also termed aggrus), a cellular
mucin-like glycoprotein expressed by kidney podocytes
(which are known to be susceptible to HIV infection [35])
and lymphatic endothelium [36-38]. Podoplanin expres-
sion was not detected on viable, but on apoptotic T-cells
and on apoptotic peripheral blood mononuclear cells
(PBMCs). However, apoptosis of HIV infected T-cells was
not associated with podoplanin expression. Nevertheless,
CLEC-2 mediated trans-infection of HIV generated in
PBMCs, indicating that these cells might express a so far
unidentified CLEC-2-ligand which can facilitate CLEC-2-
dependent HIV capture.
Methods
Cell culture and transfection
293T, 293 T-REx [19], GP2 293 (Clontech, California,
U S A )  a n d  C H O  c e l l s  w e r e  m a i n t a i n e d  i n  D u l b e c c o ' s
modified Eagle medium (DMEM) supplemented with
10% fetal calf serum (FCS, Biochrom, Germany), penicil-
lin and streptomycin. In addition, blasticidin and zeocin
were used for selection of 293 T-REx cells expressing
CLEC-2 upon induction with doxycycline (Sigma, Ger-
many). CHO Lec1 and CHO Lec2 cells [39-41] were cul-
tured in αMEM (PAA, Germany), supplemented with
10% FCS and antibiotics. B-THP, B-THP DC-SIGN, B-
THP CLEC-2 (Raji B cells that were engineered to express
DC-SIGN [42], CLEC-2 [29] or empty vector), C8166-
SEAP cells [43] and CEM×174 5.25 M7 (abbreviated
CEM×174 R5) cells [44], the latter expressing exogenous
CCR5, were cultured in RPMI 1640 medium (PAA, Ger-
many) in the presence of antibiotics and 10% FCS. All
cells were cultured at 37°C and 5% CO2. Highly purified
platelets were obtained from the "Transfusionsmedizinis-
che und Hämostaseologische Abteilung" of the University
Hospital Erlangen. Alternatively, platelets were prepared
from whole blood by centrifugation at 1200 rpm at RT.
The upper platelet-rich plasma was collected and centri-
fuged at 4000 rpm for 20 min at RT. Subsequently, the
supernatant was removed, and platelets were resus-
pended in RPMI 1640 medium supplemented with 10%
FCS and antibiotics. PBMCs were isolated from whole
b l o o d  o r  l e u k o c y t e  f i l t e r s  b y  c e n t r i f u g a t i o n  t h r o u g h  a
Ficoll gradient and either cultured in RMPI 1640 medium
supplemented with 10% FCS and antibiotics or stimu-
lated with PHA (Sigma) at a concentration of 5 μg/ml and
IL-2 (Roche) at a concentration of 10 U/ml.
Plasmids
The NL4-3-based reporter virus bearing EGFP in place of
nef was generated by splice overlap extension (SOE) PCR.
Briefly, a NL4-3 env fragment was amplified using oligo-
nucleotides pJM206 (binding upstream of the singular
HpaI restriction site in env), and pJM394 (binding to the
3' end of env and also containing the first three triplets ofChaipan et al. Retrovirology 2010, 7:47
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EGFP) and pBRNL4-3 [45] as template. EGFP was ampli-
fied from pEGFP-C1 (Clontech) using primers JM395
(binding to EGFP start sequences) and JM396 (introduc-
i ng a  M lu I si t e  do wnst r ea m of  t he  EGF P s t o p c odo n) .
Both PCR fragments were fused by SOE PCR using prim-
ers pJM206 and pJM396. The resulting env-EGFP frag-
ment was cloned via HpaI and MluI into pBRNL4-3_nef+
Δ1Δ2 [46] resulting in the generation of pBRNL4-3-EGFP
in which nef  was replaced by EGFP. Oligonucleotide
sequences (env sequences in bold; EGFP sequences in
italics, MluI restriction site underlined): pJM206 5'-
TGGAACTTCTGGGACGCAGG-3'; pJM394 5'-GCT-
CACCAT CTTATAGCAAAATCC;JM395  GCTATAA-
GATGGTGAGCAAGGGCG-3';JM396 5'-CGTACGCG
TTACTTGTACAGC-3'. The gp120-Fc-IgG1  construct
[47] was generated by amplifying a codon-optimized
gp120 (JRFL) [48] with primers gp120_BamHI 5'-GAGT-
GGATCCCTTATCGTCGTCATCCTTGTAATCC-3'
(sense) and gp120_HindIII 5'-GTACGAAGCTTGTGGA-
GAAGCTGTGGGTGAC-3' (antisense), followed by
insertion of the PCR fragment in the BamHI and HindIII
restriction sites of the Fc-IgG1 encoding plasmid pAB61
[49]. For generating the CLEC-2-Fc-IgG1  fusion con-
struct, sense primer 5'-GTACGAAGCTTTGCAGCCCC
TGTGACACAAAC-3'and antisense primer 5'-GAGTG-
GATCCAGGTAGTTTCCACCTTGG-3' were used for
PCR amplification, and the product was cloned into
pAB61 using the HindIII and BamHI restriction sites.
CLEC-2 mutants bearing single amino acid changes were
generated by overlap extension PCR. The oligonucle-
otides 5'-GCCGGATCCACCATGCAGGATGAAGATG-
GATACATC-3' (sense) and GCCGAATTCTTAAGGTA
GTTGGTCCACCTTGG (antisense) were used as outer
primers and combined with the following inner prim-
ers:5'-GATGGAAAAGGAGCCATGAATTGTGC-3'
(sense) and 5'-AGCACAATTCATGGCTCCTTTTC-
CAT-3' (antisense) for generation of mutant CLEC-2
N192A, 5'-TTGAGTTTTTGGCCGATGGAAAAGG-3'
(sense) and 5'-TCCTTTTCCATCGGCCAAAAACTCA-
3' (antisense) for mutant CLEC-2 E187A, 5'-GTTTTTG-
GAAGATGGAGCCGGAAATATGAATTGTG-3' (sense)
and 5'-AATTCATATTTCCGGCTCCATCTTCCAAAA-
3' (antisense) for mutant CLEC-2 K190A, 5'-GCAA-
CATTG TGGAATATATTGCGGCGCGCACCCATCT-
GATTC-3' (sense) and 5'-GCGCCGCAATATATT
CCACAATG-3' (antisense) for mutant CLEC-2 K150A.
For generation of DC-SIGN-Fc-IgG1, primers 5'-GTAC-
GAAGCTTGAACGCCTGTGCCACCCCTG-3' (sense)
and 5'-GAGTGGATCCCGCAGGAGGGGGGTTTG-
GGG-3' (antisense) were used. The resulting PCR frag-
ment was cloned into pAB61, using the HindIII and
BamHI restriction sites. A PCR fragment encoding the
extracellular domain of podoplanin fused to the Fc por-
tion of human immunoglobulin was generated as
described above, employing primers 5'-GCCAAGCTT-
GCCAGCACAGGCCAGCCAGAAGATG-3' (sense) and
5'-GCGGGATCCTGTTGACAAACCATCTTTCT CAA
C-3' (antisense) and inserted into the pAB61 plasmid via
the HindIII and BamHI restriction sites (italics). The
identity of all PCR amplified sequences was confirmed by
sequencing with an ABI3700 genetic analyzer (Applied
Biosystems) according to the manufacturer's instructions.
The plasmid used for transient expression of podoplanin
(podoplanin in pcDNA3) has been previously described
[38].
Viruses and transmission analyses
Replication-competent HIV-1 NL4-3, NL4-3 luc [50] and
NL4-3 EGFP were generated as described elsewhere [50].
Briefly, 293T cells were transfected with plasmids encod-
ing proviral DNA, and culture medium was changed 12 h
post transfection. Culture supernatants were harvested at
48 h post transfection and filtered through a 0.45 μm fil-
ter, aliquoted and stored at -80°C. Transmission analyses
were carried out as described [29]. Briefly, B-THP control
cells, B-THP-DC-SIGN and B-THP-CLEC-2 cells [29,42]
or platelets were incubated with virus for 3 h at 37°C, and
unbound virus was removed by washing with fresh cul-
ture medium. Cells were then incubated with CEM×174
R5 target cells and luciferase activities in cellular lysates
were determined three days after the start of the coculti-
vation by employing a commercially available system
(Promega, Germany).
Binding studies with soluble proteins
For generating soluble Zaire Ebolavirus glycoprotein
(ZEBOV-GP)-Fc- [51], DC-SIGN-Fc-, CLEC-2-Fc- and
Podoplanin-Fc-fusion proteins, 293T cells were calcium
phosphate-transfected with the respective plasmids or
pAB61 control plasmid encoding only the Fc-portion of
IgG1. For transfection of CHO and mutant cell lines,
Lipofectamine 2000 transfection reagent (Invitrogen,
Germany) was used according to the manufacturer's pro-
tocol. The cells were washed with PBS and the culture
medium was replaced by FCS-free medium at 12 h post-
transfection and supernatants were harvested 48 h post-
transfection. Subsequently, supernatants were concen-
trated using Centricon Plus-20 size-exclusion centrifugal
filters (Millipore, Germany; centrifugation at 4000 g for
15 minutes), aliquoted, and stored at -80°C. To employ
comparable amounts of soluble proteins for binding stud-
ies, Fc-fusion protein preparations were normalized by
Western blot, employing an anti-human IgG-horseradish
peroxidase conjugate for detection (Dianova, Germany).
To assess binding, 5 × 105 cells were incubated with Fc-
fusion proteins and Fc-control protein at 4°C for 45 min-
utes. Subsequently, the cells were washed with FACS buf-Chaipan et al. Retrovirology 2010, 7:47
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fer and stained with Cy5-conjugated anti-human IgG
secondary antibody for 30 minutes at 4°C. Cell-staining
w a s  t h e n  a n a l y z e d  b y  f l o w  c y t o m e t r y ,  e m p l o y i n g  a
Cytomics FC500 flow cytometer (Beckman-Coulter, Flor-
ida, USA), and data were analyzed with FCS Express
FACS analysis software (De Novo Software, Los Angeles,
USA).
Analysis of podoplanin surface expression
Analyses of podoplanin surface expression were per-
formed by flow cytometry, using the podoplanin specific
antibodies NZ-1 or 18H5 (Acris, Germany) in combina-
tion with secondary anti rat/mouse antibody coupled to
Cy5 (Dianova, Germany). Cells were incubated with 10
μg/ml antibody in PBS supplemented with 5% FCS for 30
minutes at 4°C. Subsequently, PBS supplemented with 5%
FCS was added, and the cells were pelleted by centrifuga-
tion (1200 rpm, 4°C for 5 minutes). Finally, cells were
resuspended in fixans (1.5% paraformaldehyde) and incu-
bated for 30 minutes at 4°C before staining was analyzed
by flow cytometry. For all measurements 20,000 gated
events were collected.
Knock-down of podoplanin expression by shRNA
For stable knock-down of podoplanin in 293T cells, shR-
NAs were constructed by using shRNA Hairpin Oligonu-
cleotide Sequence Designer Tool (Clontech, California,
USA). The podoplanin specific shRNA 137 contained the
target shRNA sequence, a hairpin loop region "TTCAA-
GAGA" and an antisense shRNA sequence followed by a
pol III terminator sequence. The shRNA was constructed
by annealing shRNA137sense_BamHI: 5'GATCCGC-
GAAGATGAT GTGGTGACTTTCAAGAGAAGT-
CACC ACATCATCTTCGTTTTTTACGCGTG3' and
shRNA137antisense_EcoRI: 5'AATTCACGCGTAAAAA
ACGAAGATGATGTGGTGACTTCTCTTGAAAGTCA
CCACATCATCTTCGCG3' followed by insertion of the
double stranded fragment into the retroviral vector pSI-
REN-IRES-EGFP-RetroQ [52], using restriction enzymes
BamHI and EcoRI, respectively. This vector allows stable
expression of small hairpin RNAs in transduced cells,
which can be readily identified and selected due to vector
encoded genes for puromycin resistance and EGFP
(enhanced green fluorescence protein) expression. Retro-
viral transduction was performed by transient expression
of the shRNA constructs and VSV-G in the packaging cell
line GP2-293 (Clontech, California, USA). At 48 h post
transfection, cell supernatants were harvested, and
viruses were concentrated by ultracentrifugation for 2 h
at 4°C. Pelleted virions were resuspended in 2 ml medium
containing 2 μg/ml polybrene (Sigma-Aldrich, Germany)
and were used for transduction of 1 × 106 293T cells. At
24 h post transduction, cells were washed and incubated
for 3 days. Subsequently, transduced cells were selected in
medium containing 10 μg/ml puromycin (Sigma-Aldrich,
Germany).
Apoptosis induction
For apoptosis induction cells were incubated with 1 μM
staurosporine (New England Biolabs, Germany), 25 μg/
ml cycloheximide (Sigma-Aldrich, Germany) or 0.1%
DMSO as a control in culture medium for 14 h unless
otherwise stated. Cells were stained for apoptosis with
PE-conjugated annexin V (R&D Systems, Minnesota,
USA) and for necrosis with 7-aminoactinomycin D (7-
AAD, Sigma, Germany). Specifically, cells were incubated
with 5 μl annexin V or 7-AAD for 20 min at room tem-
perature and then washed with PBS supplemented with
5% FCS. Subsequently, cells were fixed in 1.5% paraform-
aldehyde for 30 minutes at 4°C. Staining was analyzed
within 30 minutes after completion of fixation by flow
cytometry. For all measurements 20,000 gated events
were collected.
Inhibition of antibody binding by soluble podoplanin
The podoplanin specific antibodies 18H5 and NZ-1
(Acris, Germany) were pre-incubated with concentrated,
soluble podoplanin-Fc fusion protein for 30 minutes at
4°C before staining of apoptotic cells for subsequent
FACS analysis.
Statistical analyses
Statistical significance was determined by employing a
two-tailed student's t-test for paired samples.
Results
Efficient binding of soluble CLEC-2 to 293T cells does not 
require expression of the HIV-1 envelope protein
I n  o r d e r  t o  be t t e r  u n d e r s t a n d  H IV - 1  i n t e r a c t i o n s  w i t h
CLEC-2, we first asked if CLEC-2, like DC-SIGN [16],
binds to the HIV-1 envelope protein (Env). For this, we
generated soluble versions of DC-SIGN and CLEC-2 by
fusing the extracellular domain of these lectins to the Fc-
portion of human immunoglobulin. Soluble DC-SIGN
bound to control transfected 293T cells with higher effi-
ciency than the Fc-control protein (Fig. 1A), most likely
due to recognition of cellular proteins harbouring high-
mannose and/or fucose containing glycans, which are
bound by DC-SIGN [17-19]. Notably, however, binding
was substantially enhanced upon expression of the HIV-1
NL4-3 Env protein on 293T cells (Fig. 1A), indicating that
DC-SIGN binds to HIV-1 Env, as expected from pub-
lished data [16]. Finally, the interaction of soluble DC-
SIGN with control cells and Env expressing cells was spe-
cific, since binding could be inhibited by the mannose-
polymer mannan, a previously described inhibitor of DC-
SIGN interactions with ligands [16]. Soluble CLEC-2 also
bound to 293T cells with higher efficiency than the Fc-
control protein (Fig. 1A). However, in stark contrast toChaipan et al. Retrovirology 2010, 7:47
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Figure 1 CLEC-2 does not recognize the viral Env protein. (A) 293T cells were either control transfected with empty vector or transfected with an 
HIV-1 NL4-3 Env expression plasmid. Subsequently, the cells were preincubated with PBS or mannan and then DC-SIGN-Fc (left panel) or CLEC-2-Fc 
(right panel) fusion proteins or an Fc-control protein (black bars) were added. Unbound proteins were removed by washing and bound proteins de-
tected by flow cytometry. The results represent the average of the geometric mean channel fluorescence (GMCF) measured in four independent ex-
periments. Error bars indicate standard error of the mean (SEM). (B) 293T cells were transfected with DC-SIGN, CLEC-2 or empty vector and incubated 
with soluble HIV-1 Env gp120-Fc fusion protein or control Fc-protein. Unbound proteins were removed by washing and bound proteins detected by 
flow cytometry. The results represent the average ± SEM of the GMCF measured in three independent experiments. GMCF: geometric mean channel 
fluorescence, SEM: standard error of the mean.
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the results obtained with soluble DC-SIGN, the interac-
tion was not inhibited by mannan and was not enhanced
by expression of the viral Env protein. In agreement with
these results, soluble HIV-1 Env protein bound specifi-
cally to DC-SIGN but not to CLEC-2 expressing cells (Fig.
1B). We therefore concluded that CLEC-2, in contrast to
DC-SIGN, does not capture HIV-1 Env. Instead, CLEC-2
seemed to recognize a cellular factor expressed on 293T
cells, and binding to this factor did not depend on recog-
nition of high-mannose carbohydrates.
Podoplanin, a recently identified CLEC-2 ligand, is 
expressed on 293T cells
The cellular mucin podoplanin was recently shown to
interact with CLEC-2 [53]. Podoplanin is endogenously
expressed by kidney podocytes [37]. Therefore, we inves-
tigated if the kidney-derived cell line 293T also expresses
podoplanin. Flow cytometric analysis indeed revealed
high levels of podoplanin on the surface of 293T cells
(Fig. 2A). Expression was further enhanced upon trans-
fection of 293T cells with a podoplanin expression plas-
mid (Fig. 2A), and higher levels of podoplanin resulted in
more efficient binding of soluble CLEC-2 (Fig. 2B). In
contrast, no binding to the lymphoid cell line CEM×175
R5 was detected (Fig. 2B), which was podoplanin negative
(see below). We then used soluble podoplanin to confirm
the interaction with CLEC-2. For this, CLEC-2 expres-
sion was induced on 293 T-REx CLEC-2 cells, and bind-
ing of soluble podoplanin fused to the Fc-portion of
human immunoglobulin was analyzed by flow cytometry.
Efficient binding of soluble podoplanin was observed
only upon induced expression of CLEC-2, and a control
Fc protein did not bind to the CLEC-2 expressing cells
(Fig. 2C and data not shown). Thus, 293T cells, which we
and many others frequently use for production of HIV-1
stocks, express podoplanin; and podoplanin specifically
interacts with CLEC-2.
Glycosylation of podoplanin is required for efficient 
binding to CLEC-2
We next sought to elucidate the determinants governing
efficient interactions between podoplanin and CLEC-2.
For instance, it is at present unclear if glycosylation of
podoplanin is required for binding to CLEC-2. Watson
and colleagues demonstrated that binding of CLEC-2 to
the snake venom protein rhodocytin is glycosylation
independent, and defined several amino acids in CLEC-2
which contributed to efficient rhodocytin binding
[33,34]. Thus, mutations K150A, E187A, K190A and
N192A decreased binding of CLEC-2 to rhodocytin in
surface plasmon resonance binding studies [34]. We
addressed if these residues were also required for binding
to soluble podoplanin. Flow cytometric analysis showed
that all changes, with the exception of K190A were com-
patible with efficient expression of CLEC-2 (Fig. 3A).
Wild type CLEC-2 and all mutants, except K190A, bound
to soluble podoplanin with similar efficiency, indicating
that the CLEC-2 residues involved in rhodocytin binding
were not important for binding to podoplanin. Podopla-
nin contains sialylated O-glycans [54], and we next ana-
lyzed if glycosylation of podoplanin is essential for
binding to CLEC-2. For this, podoplanin-Fc fusion pro-
teins were produced in wt CHO cells or CHO cells that
due to defects in either the medial Golgi localized N-
acetylglucosaminyltransferase I (CHO Lec1) or the trans
Golgi localized CMP-sialic acid transporter (CHO Lec2)
have lost their abilities to produce complex N-glycans and
sialylated glycoconjugates, respectively [39-41]. Soluble
proteins were concentrated from cellular supernatants by
size-exclusion filtration, and Western blot analysis
showed that the podoplanin-Fc preparations contained
roughly comparable amounts of protein (Fig. 3B), while
the Fc-control protein preparation was more concen-
trated. When binding to CLEC-2 was analyzed in a
F A C S - b a s e d  a s s a y ,  p o d o p l a n i n  p r o d u c e d  i n  L e c 1  c e l l s
still bound to CLEC-2 with appreciable efficiency (Fig.
3C). In contrast, podoplanin produced in Lec2 cells and
thus almost completely lacking sialoglycoconjugates did
not show significant binding to CLEC-2 (Fig. 3C). The
observed differences indicate that the presence of sialic
acid is essential for binding to CLEC-2. Moreover,
because N-glycans are exclusively of the high-mannose
type if proteins are expressed in Lec1 cells, this finding
provides evidence that sialylated O-glycans are involved
in mediating the contact to CLEC-2. Based on the knowl-
e d g e  t h a t  E D T A  i n f l u e n c e s  b i n d i n g  p r o p e r t i e s  o f  D C -
SIGN [16], we next asked if also the interaction between
CLEC-2 and podoplanin depends on divalent ions. As
shown in Fig. 3D, treatment of DC-SIGN expressing cells
with EDTA significantly reduced binding to soluble
ZEBOV-GP-Fc, but had no effect on binding of soluble
podoplanin to CLEC-2 (Fig. 3D), indicating that divalent
ions are not required for the structural integrity of the
podoplanin binding surface of CLEC-2.
Podoplanin is incorporated into virions produced in 293T 
cells and virion incorporation is essential for CLEC-2-
dependent HIV-1 interactions with cell lines and platelets
Our results so far indicated that podoplanin is expressed
by 293T cells and that podoplanin specifically interacts
with CLEC-2. We next assessed if podoplanin is incorpo-
rated into HIV-1 released from transfected 293T cells and
if the virion incorporation of podoplanin is required for
HIV-1 interactions with CLEC-2. To address these ques-
tions, particularly the potential relevance of podoplanin
for HIV-1 interactions with CLEC-2, we employed
shRNA knock-down. We first tested a panel of podopla-
nin-specific shRNAs and identified one shRNA whichChaipan et al. Retrovirology 2010, 7:47
http://www.retrovirology.com/content/7/1/47
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efficiently reduced podoplanin expression in transiently
transfected 293T cells (data not shown). Subsequently,
this shRNA was stably introduced into 293T cells by
employing a retroviral vector, which also contained an
expression cassette for EGFP. As control, cells were trans-
duced with a retroviral vector encoding a non-sense
shRNA. After cultivation in selection antibiotics, all cells
were positive for EGFP and thus harboured the vector
Figure 2 Podoplanin is expressed on 293T cells and binds to CLEC-2. (A) 293T cells were either control transfected with empty vector or trans-
fected with a podoplanin expression construct. Cells were stained with anti-podoplanin antibody 18H5 and analyzed by flow cytometry (black filled 
area: control transfected cells stained with isotype antibody, grey filled area: control transfected cells stained with 18H5, grey line: cells transfected 
with podoplanin expression plasmid and stained with 18H5). The results of a representative experiment are shown on the left side, the average of four 
independent experiments is presented at the right side. Error bars indicate SEM. (B) The experiment was carried out as described for (A), but binding 
of soluble CLEC-2 to podoplanin or control transfected cells and to CEM×174 cells was analyzed. The results represent the average ± SEM of the GMCF 
measured in three (CEM×174) and four (293T, 293T-PDPN) independent experiments. (C) 293 T-REx CLEC-2 cells were doxycycline treated to induce 
CLEC-2 expression or PBS treated, and binding of soluble podoplanin-Fc or Fc-control protein was analyzed. The results represent the average ± SEM 
of the GMCF measured in three independent experiments. Dox: doxycycline, GMCF: geometric mean channel fluorescence, PDPN: podoplanin, SEM: 
standard error of the mean.
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Figure 3 Binding of podoplanin to CLEC-2 requires adequate podoplanin glycosylation and is independent of divalent ions. (A) The indicat-
ed CLEC-2 mutants were transiently expressed on 293T cells and expression (white bars) and binding of podoplanin-Fc (black bars) analyzed by flow 
cytometry. The results represent the average ± SEM of the GMCF measured in three independent experiments. (B) The Fc-control protein or the podo-
planin-Fc fusion protein was transiently expressed in the indicated CHO cell lines. CHO Lec1 cells are defective in N-acetylglucosaminyltransferase (no 
complex N-glycans are generated), CHO Lec2 cells lack the CMP-sialic acid transporter (no sialylated glycoconjugates are generated). The superna-
tants of the transfected cells were harvested, concentrated and analyzed by Western blot, using the podoplanin-specific D2-40 antibody [82] (top pan-
el) or a Fc-specific antibody (bottom panel). (C) The proteins generated in (B, control Fc-protein was 2-fold diluted) were incubated with CLEC-2 
expressing 293 T-REx cells and bound protein was detected by FACS. The results represent the average ± SEM of the GMCF measured in three inde-
pendent experiments. (D) Expression of DC-SIGN and CLEC-2 was induced on 293 T-REx cells by doxycycline treatment and the cells incubated with 
ZEBOV-GP-Fc or podoplanin-Fc, respectively, in the presence of PBS (dark bars) or 2 mM EDTA containing FACS buffer (white bars). Bound proteins 
were detected by flow cytometry. The results represent the average ± SEM of the GMCF measured in three independent experiments. GMCF: geo-
metric mean channel fluorescence, PDPN: podoplanin, SEM: standard deviation of the mean.
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genome (Fig. 4A). Podoplanin expression was not appre-
ciably altered in cells containing the vector encoding the
control shRNA. In contrast, cells transduced with the
vector encoding the podoplanin-specific shRNA showed
substantially (~70%) reduced podoplanin expression (Fig.
4A), indicating that the shRNA was active. Next, we
tested if podoplanin was incorporated into virions
released from control cells and from the podoplanin
Figure 4 Podoplanin is incorporated into virions released from 293T cells, and incorporation is essential for efficient CLEC-2-dependent 
HIV transmission. (A) 293T cells were transduced with retroviral vectors encoding EGFP and either a podoplanin-specific or a non-sense shRNA. 
Transduced cells were puromycin-selected and podoplanin (left panel) and EGFP expression (right panel) was determined by flow cytometry (using 
antibody 18H5). The average ± SEM of five independent experiments, for which GMCF was determined, is presented. Podoplanin expression on cells 
expressing control shRNA was set as 100%. (B) An env-defective NL4-3 proviral genome was transiently expressed in 293T cells transduced with vector 
encoding either podoplanin-specific shRNA or non-sense shRNA; the supernatants were harvested, and either processed directly or concentrated by 
size-exclusion filtration. Subsequently, the supernatants were analyzed for podoplanin and p24-content by Western blot. (C) The cells described in (A) 
were transfected with HIV-1 NL4-3 proviral DNA; the supernatants were harvested and their p24-content determined. Equal volumes of virus stocks 
containing 10 ng of p24-antigen were then incubated with the indicated B-THP cell lines and bound viruses transmitted to CEM×174 R5 targets. In 
parallel, direct infection of targets was assessed. The results represent the average ± SEM of six independent experiments carried out in triplicates with 
two independent virus stocks. Transmission of HIV-1 produced in 293T cells not transduced with shRNA-encoding vector was set as 100%. Control 
indicates B-THP cells stably transduced with empty vector. (D) The experiment was conducted as described in (C). However, HIV-1 transmission by 
platelets was examined. The results represent the average ± SEM of five independent experiments carried out in triplicates. The same virus stocks as 
in (C) were used. Mock indicates viruses produced in 293T cells not transduced with shRNA-encoding vector. GMCF: geometric mean channel fluo-
rescence, ns shRNA: none-sense shRNA, PDPN: podoplanin, SEM: standard error of the mean.
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knock-down cells. For this, the cells were transfected with
env-deficient HIV-1 proviral DNA (for augmented bio-
safety), the supernatants concentrated by size-exclusion
filtration and virions pelleted by centrifugation through a
sucrose cushion. Alternatively, unconcentrated superna-
tants were directly passed through a sucrose cushion.
Western blot analysis of these virion preparations yielded
a prominent podoplanin signal for virions generated in
control cells and a faint signal for virions generated in
podoplanin knock-down cells (Fig. 4B). These signals
were only observed for concentrated virions, and assess-
ment of p24 content showed that concentration of parti-
cles was indeed effective (Fig. 4B). Finally, a markedly
higher podoplanin signal was measured in the superna-
tants of HIV transfected compared to mock transfected
cells (data not shown), confirming that the podoplanin
signal observed in Fig. 4B was mainly due to virion-asso-
ciated protein. Thus, podoplanin is incorporated into
particles generated from 293T cells and incorporation
can be reduced by shRNA-mediated knock-down. We
then asked if reduced podoplanin incorporation affects
HIV-1 interactions with CLEC-2. For this, virions were
generated in control and podoplanin knock-down cells,
normalized for p24-content and analyzed in trans-infec-
tion experiments. Reduction of virion-incorporation of
podoplanin had no effect on DC-SIGN-dependent HIV-1
transmission by B-THP cells [42] (Fig. 4C), and infection
experiments confirmed that the viruses employed were of
comparable infectivity for target cells (Fig. 4C) and did
not infect the transmitting cells (data not shown). In con-
trast, diminished podoplanin incorporation resulted in a
pronounced reduction of viral transmission by CLEC-2
expressing B-THP cells and by platelets (Fig. 4C-D), dem-
onstrating that podoplanin incorporation into virions
produced in 293T cells is required for efficient interac-
tion with CLEC-2.
Reactivity of apoptotic cells with podoplanin-specific 
antibodies
Podocytes, which are visceral epithelial cells of the kid-
ney, express podoplanin and were found to be infected in
HIV-1 patients and to proliferate in HIV-1 associated
nephropathy [35]. We analyzed if major HIV-1 target
cells also express podoplanin. Analysis of PHA/IL-2 stim-
ulated PBMCs and the T/B-cell hybrid cell line
CEM×174, which is permissive to HIV and SIV infection
[55,56], yielded no evidence for podoplanin expression
when cells were gated for viability (Fig. 5A). Unexpect-
edly, however, CEM×174 cells and PBMCs defined as
non-viable by our gating strategy efficiently bound the
podoplanin antibody 18H5 but not an isotype-matched
control antibody (Fig. 5B and Additional file 1); note that
CEM×174 cells were serum starved to increase the per-
centage of non-viable cells. Co-staining of CEM×174 cells
with the apoptosis marker annexin V and the necrosis
marker 7-aminoactinomycin D (7-AAD) revealed that
virtually all apoptotic cells and roughly half of the
necrotic cells reacted with the podoplanin antibody (Fig.
5B). Comparable results were obtained with PBMCs (see
Additional file 1), albeit only a portion of the apoptotic
cells also expressed podoplanin. Apoptosis can result in
surface expression of proteins which are not found on the
surface of viable cells [57,58]. It is thus possible that
podoplanin expression is up-regulated during apoptosis.
However, apoptosis can also non-specifically change anti-
body reactivity of cells [59]. To discern between these
possibilities, we first asked if staining of non-viable cells
was a specific feature of the particular antibody used for
detection of podoplanin (clone 18H5). Notably, staining
of apoptotic cells was also observed with a different
podoplanin antibody (clone NZ-1 [60], data not shown),
which was generated in a different species (rat) and binds
to an epitope distinct from but overlapping with the one
recognized by 18H5 [61]. In contrast, staining of apop-
totic cells was not observed with several unrelated anti-
bodies (see Additional file 2). Moreover, binding of both
antibodies, 18H5 and NZ-1, to apoptotic cells could be
inhibited by the pre-incubation of antibodies with soluble
podoplanin before staining of cells whereas pre-incuba-
tion with a control protein had no effect on antibody
binding (Fig. 5C), indicating that antibody reactivity was
dependent on the availability of the antigen binding site.
So far , we had only analyzed cells naturally undergoing
apoptosis in culture. Therefore, we next asked if reactivity
against podoplanin antibodies could be induced by trig-
gering of apoptosis with staurosporine, a relatively non-
selective protein kinase inhibitor isolated from Strepto-
myces staurospores [62]. Indeed, treatment of CEM×174
cells and PBMCs with staurosporine induced binding of
annexin V and anti-podoplanin-specific antibodies 18H5
and NZ-1 (Fig. 5D and Additional file 1), underlining a
potential link between apoptosis induction and podopla-
nin expression.
Podoplanin is not expressed on HIV-1 infected T-cells
Apoptosis of infected and bystander cells is a prominent
feature of HIV infection [63]. We therefore asked if podo-
planin can be detected on HIV-1 infected C8166 T-cells
and PBMCs or on uninfected bystander cells. For this,
C8166-SEAP cells (Fig. 6A) and PBMCs (Fig. 6B) were
infected with a replication-competent HIV-1 variant har-
bouring EGFP and analyzed for binding of annexin V and
the podoplanin-specific antibody 18H5 at seven days post
infection, when massive cytopathic effect was visible in
infected C8166-SEAP cell cultures. Most HIV-1 infected
cells did not react with annexin V (Fig. 6, left panel), in
agreement with the published observation that HIV-1
infected cells maintain phospholipid asymmetry [64].Chaipan et al. Retrovirology 2010, 7:47
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Figure 5 Evidence that apoptotic cells express podoplanin. (A) Podoplanin expression on the indicated cell lines was assessed by flow cytometry. 
Black filled histogram: unstained cells, grey line: cells stained with isotype control antibody, grey filled histogram: cells stained with 18H5. Similar results 
were obtained in two independent experiments. (B) Apoptotic and necrotic CEM×174 express podoplanin. Cultured CEM×174 cells were serum-
starved and podoplanin expression on viable and apoptotic cells, as determined by forward and sideward scatter, analyzed by flow cytometry (left 
panel, the histograms were obtained by gating on dead or live cells, as indicated by the arrows in the scatter plot). Alternatively, the cells were co-
stained with podoplanin-specific antibody and the apoptosis marker annexin V or the necrosis marker 7-AAD, and staining analyzed by flow cytometry 
including both, live and dead cells. Black filled histogram: unstained cells, grey line: cells stained with isotype control antibody, grey filled histogram: 
cells stained with 18H5. (C) The podoplanin-specific antibody 18H5 was pre-incubated with podoplanin-Fc fusion protein or Fc-control protein before 
addition to apoptotic cells, and antibody binding was subsequently analyzed by flow cytometry. The results of a representative experiment are shown. 
Similar results were obtained in three separate experiments. (D) Serum-starved CEM×174 cells were incubated with 1 μM staurosporine for the indi-
cated times and then stained with anti-podoplanin antibody 18H5 and annexin V. Subsequently, podoplanin expression (black bars) and annexin V 
binding (white bars) were determined by flow cytometry. The results represent the average of two independent experiments and are shown relative 
to the podoplanin expression and annexin V binding at 0 hrs. The error bars indicate SEM. GMCF: geometric mean channel fluorescence, SEM: standard 
error of the mean.
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Likewise, infected cells did not bind the podoplanin-spe-
cific antibody (Fig. 6, middle panel). In contrast, podopla-
nin was readily detected on annexin V-positive cells (Fig.
6 right panel), which mainly represent uninfected
bystander cells (Fig. 6, left panel). These observations
suggest that podoplanin is not expressed on HIV-1
infected primary and immortalized T-cells and might
thus play a limited role in cellular attachment of HIV-1 in
infected patients.
Viruses generated in PBMCs are transmitted by CLEC-2
Our expression studies indicated that podoplanin is not
expressed on stimulated, viable PBMCs and T-cell lines
(Fig. 5), and that podoplanin expression is not induced in
C8166 T-cells and PBMCs by HIV-1 infection (Fig. 5).
These results raised the question if viruses generated in
PBMCs are indeed transmitted in a CLEC-2-dependent
fashion. Notably, B-THP CLEC-2 cells promoted trans-
infection of HIV-1 NL4-3 (X4-tropic) produced in 293T
cells and PBMCs, and these processes could be reduced
by CLEC-2-specific antiserum (Fig. 7A). Likewise, HIV-1
SF33 (X4-tropic) generated in PBMCs was transmitted to
T-cells by B-THP CLEC-2 cells, and transmission was
inhibited by CLEC-2 specific antiserum to an extent
which closely approached statistical significance (Fig. 7B),
suggesting that viruses generated in PBMCs harbour a
cellular factor which mediates binding to CLEC-2, but is
different from podoplanin.
Discussion
Several cellular lectins interact with the highly glycosy-
lated HIV Env protein [16,25,65-67], and virus capture by
these factors has been suggested to impact HIV spread in
and between individuals [15,16,68]. We have previously
Figure 6 Podoplanin is not expressed on HIV-infected T-cells. (A) C8166-SEAP cells were infected with an HIV-1 NL4-3 variant bearing the EGFP 
gene in place of nef. At 7 days post infection the infected cells were stained with podoplanin-specific antibody 18H5 and annexin V and analyzed by 
flow cytometry. Similar results were obtained in an independent experiment. (B) The experiment was conducted as described in (A). However, PHA 
stimulated PBMCs were infected and stained. The results were confirmed in two separate experiments.
A) C8166 T cells
100 101 102 103 104
100
101
102
103
104
100
101
102
103
104
100 101 102 103 104
100
101
102
103
104
100 101 102 103 104
15.7 27
2.7 54.7 21.5
8.1 1.6
68.8
3.7 8.6
54.6 33.1
A
n
n
e
x
i
n
 
V
P
D
P
N
P
D
P
N
GFP GFP Annexin V
B)
PBMCs
0
2
3
4
GFP GFP
P
D
P
N
4
Annexin V
P
D
P
N
19.6 0.95
74.3 5.2
12.8 1.15
80.5 5.57
3.41 11.5
58.3 26.9
100
101
102
103
104
100
101
102
103
104
100
101
102
103
104
100 101 102 103 104 100 101 102 103 104 100 101 102 103 104
A
n
n
e
x
i
n
 
VChaipan et al. Retrovirology 2010, 7:47
http://www.retrovirology.com/content/7/1/47
Page 13 of 18
reported that platelets, anucleated cell fragments which
play an essential role in hemostasis, express the HIV
attachment promoting proteins DC-SIGN and CLEC-2
[29]. Here, we show that DC-SIGN and CLEC-2 employ
fundamentally different strategies to capture HIV. DC-
SIGN binds to the HIV Env protein, while CLEC-2 recog-
nizes (a) cellular factor(s) incorporated into HIV parti-
cles. The cellular mucin-like glycoprotein podoplanin
was identified as such a factor, at least for virions gener-
ated in the widely used kidney-derived cell line 293T.
P o d o p l a n i n  w a s  n o t  e x p r e s s e d  o n  v i a b l e  T - c e l l s ,  t h e
major HIV target cell, and might thus be of minor impor-
tance for viral spread in vivo. Nevertheless, virions gener-
ated in PBMCs, which were found to be podoplanin
negative, were transmitted to T-cells in a CLEC-2-depen-
dent fashion, suggesting that PBMC-derived particles
might harbour a so far undiscovered CLEC-2 ligand.
Finally, a potential link between podoplanin expression
and apoptosis was discovered which merits further inves-
tigation.
DC-SIGN recognizes mannose-rich carbohydrates on
the surface of the HIV Env protein and requires Ca++ ions
Figure 7 HIV-1 produced in PBMCs is transmitted by CLEC-2. (A) Stocks of HIV-1 NL4-3 were generated in 293T cells (left panel) and in PBMCs (right 
panel) and used for transmission and direct infection, employing the indicated cell lines, as described for figure 4. The results of representative exper-
iments performed in triplicate are shown, error bars indicate SD. Similar results were obtained in two independent experiments (B) The experiment 
was carried out as described in (A) but transmission of HIV-1 SF33 generated in PBMC was analyzed. The results of a representative experiment per-
formed in triplicate are presented and were confirmed in a separate experiment; error bars indicate SD. C.p.s.: counts per second, SD: standard devia-
tion.
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for its structural integrity [16-19]. Consequently, DC-
SIGN bound to soluble Env, binding of soluble DC-SIGN
to 293T cells was strongly enhanced by expression of HIV
Env, and ligand binding to DC-SIGN was prevented by
the mannose-polymer mannan and chelators like EDTA
(Fig. 1). In contrast, CLEC-2 did not recognize soluble
HIV Env, binding of soluble CLEC-2 to 293T cells was
not augmented by expression of HIV Env, and mannan
and EDTA did not interfere with ligand binding to CLEC-
2 (Fig. 1). These findings confirm our previous results
obtained with virus-particles [29] and suggest that CLEC-
2 does not recognize Env, but a host cell factor which is
expressed on 293T cells. They also indicate that CLEC-2
is neither mannose-specific nor calcium-dependent.
Thus, DC-SIGN and CLEC-2 differ profoundly in their
mechanisms of ligand binding and in their ligand speci-
ficities.
The discovery of Suzuki-Inoue and colleagues [53] that
podoplanin, a cellular mucin expressed on kidney podo-
cytes [37], type I alveolar cells and lymphoid endothelial
cells [36], binds to CLEC-2 and activates CLEC-2-depen-
dent signalling, suggested that podoplanin might be the
elusive CLEC-2 ligand on 293T cells. Indeed, FACS analy-
sis revealed robust and homogenous podoplanin expres-
sion on 293T cells (Fig. 2), in agreement with recently
published reports [69,70], and binding studies with solu-
ble proteins confirmed that CLEC-2 and podoplanin
interact (Fig. 2). Watson and colleagues previously
defined amino acids in CLEC-2, which are important for
the interaction with the snake venom component rhodo-
cytin, and suggested that CLEC-2 binding to ligands
might be carbohydrate-independent [33,34]. Notably,
none of the amino acid residues important for rhodocytin
binding was critical for efficient binding to podoplanin,
while the presence of sialylated glycotopes on podoplanin
was indispensable (Fig. 3), in agreement with previous
results [54,71]. Rhodocytin and podoplanin might there-
fore engage CLEC-2 differentially, and a potential lectin-
activity of CLEC-2 requires further investigation.
The endogenous expression of podoplanin on 293T
cells and the specific interaction of podoplanin with
CLEC-2 raised the questions if podoplanin was incorpo-
rated into virions produced in 293T cells, and if incorpo-
ration of podoplanin was required for CLEC-2 binding of
these virions. Western blot analysis and knock-down of
podoplanin expression by shRNA provided affirmative
answers to both questions: Podoplanin depletion reduced
CLEC-2-, but not DC-SIGN-, dependent HIV-1 transmis-
sion by B-THP cells, and diminished transmission by
platelets by about 50% (Fig. 4). The latter finding is in
agreement with our previous observation that CLEC-2-
specific antiserum reduced HIV-1 transmission by plate-
lets by about half [29]. Podoplanin therefore joins the list
of host factors which can be incorporated into the HIV-1
envelope and impact HIV-1 infection by interacting with
their cognate ligands [9,10]. A prominent example for
such a factor is ICAM-1 which was found to be incorpo-
rated into the viral membrane, and to facilitate HIV-1
infection by binding to its ligand LFA-1 on T-cells [12].
The potential relevance of podoplanin incorporation
for HIV spread in infected individuals is critically deter-
mined by the overlap of the podoplanin expression pat-
tern with the cellular tropism of HIV. Analysis of T-cell
lines and PBMCs for podoplanin expression yielded neg-
ative results (Fig. 5), at least when viable cells were ana-
lyzed (see below), indicating that HIV particles generated
in patients might not harbour podoplanin. The exception
might be viruses released from kidney podocytes which
have been documented to express podoplanin [37] and to
be susceptible to HIV infection [35]. However, the biolog-
ical relevance of this process is questionable. In this con-
text, it also needs to be noted that podoplanin expression
is up-regulated in many tumours including Kaposi sar-
coma [72,73]. Podoplanin/CLEC-2-dependent platelet
stimulation by tumour cells promotes hematogenous
tumour metastasis [71,74], possibly by inducing growth
factor secretion by platelets and by promoting formation
of a "platelet cap", which protects the tumour from
mechanical forces. Thus, podoplanin might play a role in
the development of the AIDS-associated Kaposi sarcoma,
but is unlikely to modulate HIV spread in patients. Nev-
ertheless, HIV-1 produced in PBMCs was transmitted to
target cells in a CLEC-2-dependent fashion (Fig. 7), sug-
gesting that primary T-cells might express a so far unrec-
o g n i z e d  C L E C - 2  l i g a n d  ( a  h y p o t h e s i s  a l s o  r a i s e d  b y
others [75]), which is incorporated into the viral envelope
and which facilitates HIV transmission by CLEC-2. Our
ongoing studies are devoted to the identification of this
factor.
Podoplanin was not detected on viable CEM×174 cells
(a T/B cell hybrid) and PBMCs, as determined by our gat-
ing strategy and by co-staining with the apoptosis and
necrosis markers annexin V and 7-AAD, respectively
(Fig. 5 and Additional file 1). In contrast, we observed
efficient reactivity of two different podoplanin antibodies
with non-viable cells, raising the intriguing possibility
that podoplanin might be expressed at the cell surface in
the context of apoptosis. Apoptosis can indeed alter
expression of surface markers [57,58,76] but might also
modulate antibody reactivity of cells [59], making the
analyses of podoplanin expression by apoptotic cells a
technically challenging task. Our findings that two anti-
bodies, 18H5 and NZ-1, which were generated in differ-
ent species and recognize different but overlapping
epitopes in podoplanin [61], both specifically bind to
apoptotic cells (Fig. 5 and data not shown), and that this
reactivity depends on the availability of the antigen-bind-
ing site (Fig. 5C) suggests to us that binding is most likelyChaipan et al. Retrovirology 2010, 7:47
http://www.retrovirology.com/content/7/1/47
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specific. Furthermore, nested RT-PCR detected podopla-
nin message in CEM×174 cells (data not shown), suggest-
ing low levels of podoplanin expression in these cells.
Importantly, the podoplanin message did not appreciably
increase upon apoptosis induction, and treatment with
cycloheximide did not block specific staining of apoptotic
cells with podoplanin antibodies (data not shown).
Therefore, one must assume that podoplanin protein (or
an antigenically related protein) is present within
CEM×174 cells and other cell types, and that the protein
becomes accessible to antibody staining only upon induc-
tion of apoptosis. If the latter process is due to specific
transport of podoplanin to the cell surface or to mem-
brane disintegration during apoptosis could not be con-
clusively determined. Regardless of the mechanism
underlying reactivity of apoptotic cells with podoplanin-
specific antibodies, podoplanin was not detected on HIV
infected viable and apoptotic cells (Fig. 6), indicating that
podoplanin expression is not altered in the context of
HIV infection.
Collectively, our data help to understand how HIV
interacts with CLEC-2, an HIV attachment factor on
platelets. Several lines of evidence suggest that this inter-
action could impact HIV spread in infected patients. For
one, thrombocytopenia (reduced platelet count) is fre-
quent in HIV/AIDS patients [77], and it is conceivable
that CLEC-2-dependent binding of HIV to platelets
results in platelet clearance and thus contributes to
reduced platelet counts. In addition, the interaction of
HIV with CLEC-2 on platelets might induce platelet acti-
vation, which was found to be associated with HIV infec-
tion [78]. Moreover, CLEC-2-dependent HIV binding to
platelets might result in trans-infection or virus degrada-
tion [28,29], and both processes could impact viral load
and disease development. Finally, it is worth noting that
liver sinusoidal endothelial cells and megakaryocytes also
express CLEC-2 [66] and that both cell types are suscepti-
ble to HIV infection [79-81], which might be modulated
by CLEC-2. In summary, CLEC-2 is expressed on several
cell types exposed to HIV in patients and thus has the
potential to modulate viral spread.
Conclusions
Our results highlight that incorporation of cellular factors
can alter HIV attachment to cells and cell to cell trans-
mission. While podoplanin is unlikely to be incorporated
into HIV particles produced in infected patients, our
results indicate that HIV might incorporate a functional
analogue of podoplanin in vivo, and that this process
might promote virus binding to CLEC-2 positive cells.
The identification of the respective factor and the clarifi-
cation of the potential connection between podoplanin
expression and apoptosis are interesting tasks for future
research.
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